Natera, Inc. (NTRA) reported a robust first quarter for 2026, achieving $697 million in revenue—up 39% year-over-year—while processing over 1 million tests for the first time in a single quarter. This growth was primarily driven by strong performances in clinical oncology, which saw a 55% increase in unit volume, and women’s health, where the new Fetal Focus test is rapidly gaining traction. Management raised revenue and gross margin guidance, now targeting a midpoint of 65%, reflecting confidence in sustained demand and operational efficiency.

The company’s expansion into the Japanese market, with expected PMDA approval for its Signatera product, could significantly enhance its addressable market, particularly in colorectal cancer. Additionally, increased R&D spending signals a commitment to advancing clinical trials that could further bolster its product offerings and market share.

For market professionals, Natera’s strong quarterly results and strategic initiatives suggest an upward trajectory in both revenue and market position, making it a stock to watch as it capitalizes on its technological advancements and market expansions.

Source: fool.com